Skip to main content

Table 2 Mean change from baseline in 6MWT, BDI scores, and NT-proBNP levels after treatment with ambrisentan (ITT population): post-hoc analysis

From: Efficacy and safety of ambrisentan in Chinese patients with connective tissue disease-pulmonary arterial hypertension: a post-hoc analysis

Efficacy measure

Time point

CTD-PAH(N = 71)

IPAH/HPAH (N = 50)

Between-group difference$

6MWT, m (LOCF)

Baseline

366.4 (60.4)

397.3 (48.1)

 

Change from baseline (Week 12)

63.8 (57.4)

45.5 (69.7)

−18.39

p value

< 0.001*

< 0.001*

0.115¥

Change from baseline (Week 24)

73.2 (84.6)

62.2 (81.9)

−10.97

p value

< 0.001*

< 0.001*

0.478¥

BDI score (LOCF)

Baseline

2.7 (1.4)

2.3 (1.5)

 

Change from baseline (Week 12)

−0.6 (1.1)

−0.2 (1.9)

0.35

p value

< 0.001§

0.427§

0.203

Change from baseline (Week 24)

−0.4 (1.70)

−0.2 (1.96)

0.19

p value

0.002§

0.138§

0.377

NT-proBNP, ng/L (Observed data)

Baseline

1837.5 (2209.6)

1281.3 (1140.6)

 

Change from baseline (Week 12)

−1156.8 (1735.4)

−450.3 (699)

706.49

p value

< 0.001§

< 0.001§

0.007

Change from baseline (Week 24)

−1095.5 (1587.7)

− 396.6 (738.5)

698.89

p value

< 0.001§

< 0.001§

0.011

  1. BDI Borg Dyspnoea Index, CTD connective tissue disease, HPAH Heritable PAH, IPAH Idiopathic PAH, ITT intent-to-treat, NT-ProBNP N-terminal pro hormone B-Type Natriuretic Peptide, 6MWT six-minute walk test